Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986242 |
| Synonyms | |
| Therapy Description |
BMS-986242 is a selective inhibitor of indoleamine-2, 3-dioxygenase 1 (IDO1), with potential antitumor activity (PMID: 33603977). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986242 | BMS986242|BMS 986242 | IDO1 Inhibitor 13 | BMS-986242 is a selective inhibitor of indoleamine-2, 3-dioxygenase 1 (IDO1), with potential antitumor activity (PMID: 33603977). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03369223 | Phase Ib/II | BMS-986242 BMS-986249 + Nivolumab | An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | Completed | USA | ROU | POL | ITA | FIN | ESP | DEU | CAN | AUS | ARG | 1 |